The clinical trials for the implementation of the Cuban biopharmaceutical drug Heberprot-P in patients with diabetic foot in Russia show today the effectiveness of the medicine, with prospects of being extended to a larger number of regions.
We move satisfactorily in the collaboration with the regions in the medical-pharmaceutical issue, specifically the introduction of Heberprot P in pilot studies, Cuban ambassador, Emilio Lozada, said in an interview with Prensa Latina.
Lozada recalled that the medicine, unique in the world prescribed for treating diabetic foot ulcer, was registered in Russia in February 2014, and then included in the list of Essential and Vital Medicines within the Federation, earlier this year.
Pilot studies have been successfully developed in the region of Kaluga, Nizhny Novgorod, Sverdlovsk, and Kursk, with prospects of extending the clinical trials to other regions, such as Tver, Tula, Oriol, Ivanovo, Rostov, and Irkutsk, in Siberia.
The diplomat said about this issue that a seminar for about 200 Russian doctors was held with that purpose in Oriol on the application instruction of the biopharmaceutical medicine, which have been also experimentally carried out in the republics of Tatarstan and Bashkotarstan, according to the source.
Lozada stressed the progress reached in recent years in promoting the Cuban tourism products in St. Petersburg, the second largest city in Russia, where the opening in the coming months of a Havanatur subsidiary company is expected.
Negotiations with the Sverdlovsk region and the republic of Tatarstan are also strengthened. Along with the pharmaceutical products and services, tourism is a pivot to boost trade and business relations with the regions, the ambassador said.
The Cuban biopharmaceutical Heberprot-P received the Gold Medal of the World Intellectual Property Organization (WIPO) in 2011. Developed at the Center for Genetic Engineering and Biotechnology, the injectable product won the laurels for his contribution to the treatment of more 18 000 patients with chronic ulcer of diabetic foot -complicación suffering from diabetes- in Cuba and other nations.
It is a novel and unique drug prescribed for the treatment of diabetic foot ulcer (UPD) based on the recombinant human growth factor (FCHrec.) by intralesional infiltration directly into the wound site. Therapy HEBERPROT-P fills the space of an unmet medical need for the treatment of complex diabetic foot ulcers.
This medicine accelerates the healing of injuries, decreases the number of amputations of lower limbs and improves the quality of life of patients. It was recorded in Cuba since 2006, and in Algeria in 2008; in Argentina, Uruguay and the Dominican Republic in 2009; in Venezuela, Ecuador, Mexico, Paraguay and Libya in 2010; in 2011 in Colombia, Guatemala, Georgia and Ukraine, and Vietnam did in 2012.
Also in the Philippines and Panama, both in 2012, Costa Rica (2013), while Russia, Turkey, El Salvador, Peru and Belarus recorded it in 2014. Other registration actions are carried out in the territories of Europe, China, Brazil, South Africa and the Arabian Gulf.
According to Cuban health authorities, through the use of Heberprot-P on the island most diabetic patients have a life expectancy similar to that of other people life, reducing by 78 percent relative risk of amputation.
Situation in the United States:
In an article in the American magazine MEDICC (Medical Education Cooperation with Cuba) noted that because of estrangement of US from Cuba, most Americans suffering from diabetes may be unaware that our biotech industry is booming, since the 1980s one of the ‘big three’ in the global South (with Brazil and India).
Detailed that some 29.1 million Americans have diabetes, of which almost 8 million are unaware of their condition. The report also reveals that each year, between 70,000 and 80,000 diabetics in the American nation are amputees by one of the most devastating complications of the disease: diabetic foot ulcers.
Besides the impact on human health, must be added the cost to patients and for federal programs, estimated at about 250 000 million dollars annually, with patients suffering from diabetic foot ulcer paying double what they invest other diabetics for care. And this does not count the cost of years of disability, associated with loss of income and the deepest poverty.
Because of the US embargo against Cuba, many patients are not aware of the progress in the Cuban biotechnology industry. AND WORST: Because this is a Cuban product, US physicians can not prescribe the Heberprot-P to their patients, since the Department of Foreign Assets Control (OFAC, charged with enforcing the US blockade against Cuba) Treasury Department denied a license for trials and sales in 2010 and later, in 2014, the agency gave a license only for clinical trials, but refused to give the green light to future sales, even if the FDA approves the drug is safe and effective.
We are talking about the lives of 70,000 to 80,000 people who are able to avoid trauma and situations that engender an amputation; situation that is multiplied several times because relatives also suffer with the sick and affect both psychologically and financially.
It is a sad madness. Another absurd, inhuman and disastrous consequence of the economic, commercial and financial blockade against Cuba, which harms not only Cubans but also as in this case, the American people, and violate their human rights.
(With information from Prensa Latina, Telesur, http://heberprot-p.cigb.edu.cu/index.php/es/)